Case 1-2005: A 35-year-old woman with difficulty walking, headache, and nausea

New England Journal of Medicine

Volumn 352, Issue 2, 2005, Pages 185-194

  Batchelor, Tracy T ^a   Buchbinder, Bradley R ^a   Harris, Nancy Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINATE CALCIUM; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ANAMNESIS; ARTICLE; B CELL LYMPHOMA; BONE MARROW DISEASE; BRAIN BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORPUS CALLOSUM; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; INFUSION; LARGE CELL LYMPHOMA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; STEREOTAXIC SURGERY; TREATMENT OUTCOME; BIOPSY; BRAIN TUMOR; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; HEADACHE; METHODOLOGY; MOTOR DYSFUNCTION; NAUSEA; PARIETAL LOBE; PATHOLOGY; RADIOGRAPHY; TUMOR RECURRENCE;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY; BRAIN NEOPLASMS; CORPUS CALLOSUM; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEADACHE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MOVEMENT DISORDERS; NAUSEA; NEOPLASM RECURRENCE, LOCAL; PARIETAL LOBE; STEREOTAXIC TECHNIQUES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 11844300350     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcpc049033     Document Type: Article

References (42)

1. Atlas SW, Lavi E, Fisher PG. Intraaxial brain tumors. In: Atlas SW, ed. Magnetic resonance imaging of the brain and spine. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2002:565-693.
2. Roman-Goldstein SM, Goldman DL, Howieson J, Belkin R, Neuwelt EA. MR of primary CNS lymphoma in immunologically normal patients. AJNR Am J Neuroradiol 1992;13:1207-13.
3. Ruiz A, Post MJD, Bundschu C, Ganz WI, Georgiou M. Primary central nervous system lymphoma in patients with AIDS. Neuroimaging Clin N Am 1997;7:281-96.
4. Koeller KK, Smirniotopoulos JG, Jones RV. Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 1997;17:1497-526.
5. Johnson BA, Fram EK, Johnson PC, Jacobowitz R. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 1997;18:563-72.
6. Jenkins CNJ, Colquhoun IR. Characterization of primary intracranial lymphoma by computed tomography: an analysis of 36 cases and a review of the literature with parricular reference to calcification, haemorrhage, and cyst formation. Clin Radiol 1998;53:428-34.
7. Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR. Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol 2001;176:1319-26.
8. Bühring U, Herrlinger U, Krings T, Thiex R, Weller M, Küker W. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-6.
9. Coulon A, Lafitte F, Hoang-Xuan K, et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 2002;12:329-40.
10. A clinical evaluation of the international Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
11. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma: the Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383-97.
12. Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975;31:Suppl 2:29-43.
13. Bhan AK, Nadler LM, Stashenko P, McCluskey RT, Schlossman SF. Stages of B cell differentiation in human lymphoid tissue. J Exp Med 1981;154:737-49.
14. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53.
15. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A 1998;95:11816-21.
16. Carbone A, Gaidano G, Gloghini A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998;91:747-55.
17. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-51.
18. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
19. Engelhard M, Brittinger G, Huhn D, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood 1997;89:2291-7.
20. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
21. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063-9.
22. Batchelor TT, ed. Lymphoma of the nervous system. Boston: Butterworth-Heinemann, 2004.
23. Statistical report: primary brain tumors in the United States, 1995-1999. Hinsdale, Ill.: Central Brain Tumor Registry of the United States, 2002. (Accessed December 17, 2004, at http://www.cbtrus.org/2002/2002report.pdf.)
24. Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer 1988;62:2461-5.
25. Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. J Natl Cancer Inst 1996;88:675-9.
26. Kadan-Lottick NS, Skluzarek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002;95:193-202.
27. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000;92:261-6.
28. Ferreri AJM, Blay J-Y, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72.
29. DeAngelis LM, Yahalom J, Heinemann M-H, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990;40:80-6.
30. Henry JM, Hefther RR Jr, Dillard SH, Earle KM, Davis RL. Primary malignant lymphomas of the central nervous system. Cancer 1974;34:1293-302.
31. Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system: results of treatment of 11 cases and review of the literature. J Neurosurg 1986;65:600-7.
32. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
33. Ferreri AJM, Abrey LE, Blay J-Y, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407-14.
34. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71.
35. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-63.
36. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60.
37. Batchelor TT, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-9.
38. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151-6.
39. Mavrommatis CG, Daskalakis GJ, Papageorgiou IS, Antsaklis AJ, Michalas SK. Non-Hodgkin's lymphoma during pregnancy - case report. Eur J Obstet Gynecol Reprod Biol 1998;79:95-7.
40. Plotkin SR, Batchelor TT. Primary nervous system lymphoma. Lancet Oncol 2001;2:354-65. [Erratum, Lancet Oncol 2001;2:455.]
41. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004;10:5643-6.
42. Soussain C, Hoang-Xuan K, Levy V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Bull Cancer 2004;91:189-92.